Mind Medicine (MindMed) Stock price Deutsche Boerse AG

Equities

MMQ

CA60255C8850

Real-time Estimate Tradegate 11:11:39 2024-03-28 am EDT 5-day change 1st Jan Change
9.088 EUR +0.20% Intraday chart for Mind Medicine (MindMed) -3.86% +154.14%
Sales 2024 * - Sales 2025 * - Capitalization 670M 620M
Net income 2024 * -91M -84.25M Net income 2025 * -104M -96.28M EV / Sales 2024 * -
Net cash position 2024 * 184M 171M Net cash position 2025 * 99.5M 92.12M EV / Sales 2025 * -
P/E ratio 2024 *
-6.12 x
P/E ratio 2025 *
-6.64 x
Employees 57
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Mind Medicine Inc. announced that it has received $75 million in funding from Deep Track Capital, LP, Commodore Capital CI
RBC Raises Price Target on Mind Medicine (MindMed) to $22 From $15, Keeps Outperform, Speculative Risk MT
Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder CI
Sector Update: Health Care Stocks Gain Late Afternoon MT
Sector Update: Health Care Stocks Stronger in Afternoon Trading MT
Roth MKM Raises Price Target on Mind Medicine to $36 From $25, Keeps Buy Rating MT
Mind Medicine Gets FDA Breakthrough for Anxiety Treatment, Sees $175 Million in Proceeds From Stock Offerings; Shares Jump MT
Transcript : Mind Medicine Inc. - Special Call
Mind Medicine Inc. Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data from Phase 2B Study of MM120 for Generalized Anxiety Disorder CI
Mind Medicine Inc. announced that it expects to receive $75 million in funding from Deep Track Capital, LP, Commodore Capital CI
RBC Lifts Price Target on Mind Medicine (MindMed) to $15 From $14, Notes Imminent Durability Data; Outperform, Speculative Risk Kept MT
Transcript : Mind Medicine Inc., 2023 Earnings Call, Feb 28, 2024
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mind Medicine Inc. Provides Anticipated Production Milestones for 2024 CI
More news

Latest transcript on Mind Medicine (MindMed)

1 day+0.42%
1 week-3.86%
Current month+57.94%
1 month+81.74%
3 months+155.95%
6 months+160.61%
Current year+154.14%
More quotes
1 week
8.54
Extreme 8.54
9.87
1 month
4.89
Extreme 4.888
9.87
Current year
3.21
Extreme 3.214
9.87
1 year
2.22
Extreme 2.218
9.87
3 years
1.96
Extreme 1.96
75.00
5 years
1.96
Extreme 1.96
75.00
10 years
1.96
Extreme 1.96
75.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 21-01-13
Director of Finance/CFO 52 22-05-22
President 71 20-02-27
Members of the board TitleAgeSince
Director/Board Member 66 21-09-28
Director/Board Member 60 22-08-10
Director/Board Member 68 23-06-20
More insiders
Date Price Change Volume
24-03-28 8.6 -5.18% 206
24-03-27 9.07 +0.78% 1,950
24-03-26 9 -7.26% 680
24-03-25 9.705 -1.67% 1,452
24-03-22 9.87 +10.34% 604

Delayed Quote Deutsche Boerse AG, March 28, 2024 at 09:40 am EDT

More quotes
Mind Medicine (MindMed) Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. The Company is developing a pipeline of drug candidates, targeting the serotonin, dopamine and acetylcholine systems. This specifically includes pharmaceutically optimized drug products derived from the psychedelic and empathogen drug classes, including lysergic acid diethylamide (LSD), R(-)-methylenedioxymethamphetamine (MDMA) and zolunicant, or 18-methoxycoronaridine (MC), a congener of ibogaine. The Company's subsidiaries include Mind Medicine, Inc. (MindMed US), HealthMode, Inc., MindMed Pty Ltd., and MindMed GmbH.
Sector
-
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.5 USD
Average target price
32.67 USD
Spread / Average Target
+243.86%
Consensus
  1. Stock
  2. Equities
  3. Stock Mind Medicine (MindMed)
  4. Stock Mind Medicine (MindMed) - Deutsche Boerse AG